Table 6.
Multivariate model based on accelerometry data for bouts defined as ≥6 METs per minute for a duration of ≥10 minutes.
| Model | Estimate | Standard Error | F-Value | P-value | R-Square for Model |
|---|---|---|---|---|---|
| Dependent Variable: Bouts per Day | 0.0807 | ||||
| Age | 0.0029 | 0.0011 | 6.67 | 0.0099 | |
| BMI | 0.0009 | 0.0013 | 0.48 | 0.4881 | |
| Sex (Women versus Men) | −0.0090 | 0.0151 | 0.36 | 0.5501 | |
| Race/Ethnicity (White is the reference group) | 3.27 | 0.0204 | |||
| African-American/Black | −0.0399 | 0.0174 | |||
| Hispanic | 0.0562 | 0.0307 | |||
| Other/Mixed/Missing | −0.0138 | 0.0365 | |||
| Baseline Fitness (maximal METs) | 0.0455 | 0.0045 | 100.85 | <0.0001 | |
| Diabetes Medication (No Glucose Lowering Medication is the Reference Group) | 0.72 | 0.6062 | |||
| Glucose Lowering Medication (Not including insulin or thiazolidinedione) | −0.0030 | 0.0210 | |||
| Thiazolidinedione | −0.0254 | 0.0233 | |||
| Insulin Alone | 0.0247 | 0.0378 | |||
| Insulin + Glucose Lowering Medication (Not including thiazolidinedione) | −0.0266 | 0.0310 | |||
| Insulin + Thiazolidinedione | −0.0148 | 0.0309 | |||
| Without Baseline history of CVD | 0.0074 | 0.0191 | 0.15 | 0.6993 | |
| Dependent Variable: Minutes per Bout * | 0.0985 | ||||
| Age | −0.0751 | 0.0626 | 1.44 | 0.2306 | |
| BMI | −0.0223 | 0.0801 | 0.08 | 0.7805 | |
| Sex (Women versus Men) | 0.8540 | 0.8304 | 1.06 | 0.3042 | |
| Race/Ethnicity (White is the reference group) | 1.54 | 0.2038 | |||
| African-American/Black | 2.1024 | 1.0996 | |||
| Hispanic | 1.8014 | 1.5373 | |||
| Other/Mixed/Missing | −0.0441 | 2.1904 | |||
| Baseline Fitness (maximal METs) | 1.2454 | 0.2310 | 29.06 | <0.0001 | |
| Diabetes Medication (No Glucose Lowering Medication is the Reference Group) | 0.33 | 0.8929 | |||
| Glucose Lowering Medication (Not including insulin or thiazolidinedione) | 1.3583 | 1.1174 | |||
| Thiazolidinedione | 1.3329 | 1.2465 | |||
| Insulin Alone | 1.6337 | 2.1046 | |||
| Insulin + Glucose Lowering Medication (Not including thiazolidinedione) | 1.1841 | 1.8220 | |||
| Insulin + Thiazolidinedione | 1.3074 | 1.6948 | |||
| Without Baseline history of CVD | 0.3069 | 1.1297 | 0.07 | 0.7860 | |
| Dependent Variable: METs per Minute * | 0.2538 | ||||
| Age | −0.0093 | 0.0073 | 1.62 | 0.2093 | |
| BMI | −0.0201 | 0.0094 | 4.58 | 0.0327 | |
| Sex (Women versus Men) | −0.2684 | 0.0972 | 7.62 | 0.0060 | |
| Race/Ethnicity (White is the reference group) | 0.82 | 0.4853 | |||
| African-American/Black | −0.1302 | 0.1287 | |||
| Hispanic | 0.0929 | 0.1800 | |||
| Other/Mixed/Missing | 0.2488 | 0.2565 | |||
| Baseline Fitness (maximal METs) | 0.2319 | 0.0270 | 73.48 | <0.0001 | |
| Diabetes Medication (No Glucose Lowering Medication is the Reference Group) | 0.23 | 0.9498 | |||
| Glucose Lowering Medication (Not including insulin or thiazolidinedione) | 0.0993 | 0.1308 | |||
| Thiazolidinedione | 0.0542 | 0.1459 | |||
| Insulin Alone | 0.1068 | 0.2464 | |||
| Insulin + Glucose Lowering Medication (Not including thiazolidinedione) | 0.1143 | 0.2133 | |||
| Insulin + Thiazolidinedione | 0.1854 | 0.1984 | |||
| Without Baseline history of CVD | 0.0726 | 0.1323 | 0.30 | 0.5832 | |
| Dependent Variable: MET-minutes * | 0.1462 | ||||
| Age | −0.7787 | 0.5823 | 1.79 | 0.1817 | |
| BMI | −0.4582 | 0.7447 | 0.38 | 0.5386 | |
| Sex (Women versus Men) | 3.1983 | 7.246 | 0.17 | 0.6790 | |
| Race/Ethnicity (White is the reference group) | 0.94 | 0.4233 | |||
| African-American/Black | 12.5487 | 10.2294 | |||
| Hispanic | 18.1756 | 14.3007 | |||
| Other/Mixed/Missing | 1.7140 | 20.3772 | |||
| Baseline Fitness (maximal METs) | 14.8832 | 2.1492 | 47.95 | <0.0001 | |
| Diabetes Medication (No Glucose Lowering Medication is the Reference Group) | 0.45 | 0.8144 | |||
| Glucose Lowering Medication (Not including insulin or thiazolidinedione) | 14.3984 | 10.3947 | |||
| Thiazolidinedione | 14.3224 | 11.5961 | |||
| Insulin Alone | 16.3091 | 19.5786 | |||
| Insulin + Glucose Lowering Medication (Not including thiazolidinedione) | 10.5168 | 16.9496 | |||
| Insulin + Thiazolidinedione | 16.4032 | 15.7665 | |||
| Without Baseline history of CVD | 1.9710 | 10.5095 | 0.04 | 0.8513 |
*
Indicates that data represent participants who reported ≥1 bout during the observation period that met the criteria of ≥6 METs per minute and ≥10 minutes for that bout.